+0.05 (+2.29%)
4:39:01 PM EDT: $2.20 -0.03 (-1.35%)

Gbs Inc Announces Its Pre-Submission Package Is With The FDA

Published: 10/13/2021 13:44 GMT
GBS Inc (GBS) - Gbs Inc. Announces Its Pre-submission Package is With the FDA.
Gbs-proposed 3 Step Clinical Plan Involves Generation of Prospective Data,to Explore Relationship Between Salivary Glucose and Plasma Glucose.
Gbs-next Phase Development of Algorithm Between Plasma and Salivary Glucose,final Stage Confirm Algorithm,generate Data for Regulatory Submission.
Gbs-for First Phase Intends to Recruit 20-40 Subjects, is Currently Finalizing Arrangements With US Based Clinical Research Sites.
Gbs - Developing a Saliva Based Glucose Test on Biosensor Platform to Be Used in Point-of-care Setting.
Gbs - Intends to Provide People Living With Diabetes a More Favorable Solution to Finger-prick Blood Glucose Testing.